Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**ARTISS** is a Baxter human plasma-derived, low-thrombin fibrin sealant for topical surgical tissue adhesion. It is a two-component product containing human fibrinogen and human thrombin; when mixed at the surgical site, thrombin converts fibrinogen to fibrin, creating an adherent fibrin matrix. Synthetic aprotinin delays fibrin degradation by inhibiting fibrinolysis. ARTISS is FDA-approved for adherence of autologous skin grafts to surgically prepared burn wound beds and for adherence of tissue flaps during facial rhytidectomy. It is not indicated as an adjunct to hemostasis. ([fda.gov](https://www.fda.gov/media/71723/download))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ARTISS.